Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Breakthrough May Revolutionize Preclinical Imaging

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
A novel imaging technique for disease studies, translational research, and drug discovery will soon be made available to the biotechnology research community.

Bruker (Billerica, MA, USA) has announced the world’s first magnetic particle imaging (MPI) system, a novel technology for preclinical imaging. The MPI tomographic imaging technique relies on the detection of the magnetic properties of iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images. The system has been used to produce images that accurately captured the real-time physiological activity of a mouse's cardiovascular system,

The Bruker preclinical MPI scanner was developed in collaboration with Royal Philips (Amsterdam, The Netherlands), in a partnership that combined Bruker’s leadership in analytical magnetic resonance instruments with Philips’ strengths in medical imaging technology. The partners will co-market the preclinical MPI scanner.

Dr. Michael Heidenreich, technical director at Bruker, said, "We are very pleased about this breakthrough in preclinical imaging and our collaboration with Philips on this exciting technology. Magnetic particle imaging is a novel imaging modality that is expected to enable scientists to address an extensive range of new issues in preclinical research. MPI nicely complements Bruker’s preclinical imaging product portfolio of now nine different modalities. The highly sensitive visualization of functional characteristics in vivo at high temporal resolution offers great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI."

"Magnetic particle imaging represents a fundamentally new imaging modality with an exceptional ability to image in vivo functional behavior," said Homer Pien, chief technology officer at Philips. "We are particularly excited about its potential for providing new insights into cardiovascular disease, cancer, and stem cell therapies. Going forward, I am convinced that the results from the research studies conducted with preclinical MPI systems will provide valuable guidance for our ongoing development of a whole-body clinical MPI system."

Related Links:
Bruker
Royal Philips


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.